Telmisartan protects 5/6 Nx rats against renal injury by enhancing nNOS-derived NO generation via regulation of PPARγ signaling

American Journal of Translational Research

Volumn 6, Issue 5, 2014, Pages 517-527

  Zou, Rong ^a   He, Yong ^a,b   Li, Yue Qiang ^a   Han, Ming ^a   Ma, Zu Fu ^a   Liu, Xiao Cheng ^a   Zeng, Rui ^a   Shao, Jv Fang ^a   Guo, Yan Chao ^a,c   He, Xiao Yu ^c   Yang, Ping ^c   Xu, Gang ^a   Wang, Cong Yi ^c   Yao, Ying ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Department of Nephrology The Fifth City Hospital of Wuhan   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

5 6 nephrectomy; CKD; Nnos; PPAR ; Telmisartan

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ALBUMIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRATE; NITRIC OXIDE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EDITORIAL; GENE EXPRESSION; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MORTALITY; NEPHRECTOMY; NONHUMAN; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

RATTUS;

EID: 84908058628     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Editorial

References (28)

1. Schmidt RJ and Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58: 1261-1266.
2. Erdely A, Freshour G, Smith C, Engels K, Olson JL and Baylis C. Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat. Am J Physiol Renal Physiol 2004; 287: F81-F89.
3. Erdely A, Wagner L, Muller V, Szabo A and Baylis C. Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol 2003; 14: 2526-2533.
4. Szabo AJ, Wagner L, Erdely A, Lau K and Baylis C. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int 2003; 64: 1765-1771.
5. Tain YL, Muller V, Szabo AJ, Erdely A, Smith C and Baylis C. Renal cortex neuronal nitric oxide synthase in response to rapamycin in kidney transplantation. Nitric Oxide 2008; 18: 80-86.
6. Hostetter TH, Olson JL, Rennke HG, Venka-tachalam MA and Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001; 12: 1315-1325.
7. Wagner L, Riggleman A, Erdely A, Couser W and Baylis C. Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int 2002; 62: 532-536.
8. Baylis C, Atzpodien EA, Freshour G and Engels K. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003; 307: 854-860.
9. Muller V, Szabo AJ, Erdely A, Tain YL and Baylis C. Sex differences in response to cyclosporine immunosuppression in experimental kidney transplantation. Clin Exp Pharmacol Physiol 2008; 35: 574-579.
10. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 2008; 294: F1-F9.
11. Szabo AJ, Wagner L, Erdely A, Lau K and Baylis C. Renal neuronal nitric oxide synthase protein expression as a marker of renal injury. Kidney Int 2003; 64: 1765-1771.
12. Benson SC, Pershadsingh HA, Ho CI, Chit-tiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA and Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodula-ting activity. Hypertension 2004; 43: 993-1002.
13. Yuen CY, Wong WT, Tian XY, Wong SL, Lau CW, Yu J, Tomlinson B, Yao X and Huang Y. Telmisartan inhibits vasoconstriction via PP-ARgamma-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 2011; 90: 122-129.
14. Yang J, Ning Y, Qiu J, He JS, Li W, Ma ZF, Shao JF, Li YQ, Zeng R, Zhang M, Cheng J, Chen SF, Xu G, Wang CY and Yao Y. TJ0711, a novel vasodilatory beta-blocker, protects SHR rats against hypertension induced renal injury. Am J Transl Res 2013; 5: 279-290.
15. Yang P, Zhang Y, Xu J, Zhang S, Yu Q, Pang J, Rao X, Kuczma M, Marrero MB, Fulton D, Kraj P, Su Y and Wang CY. SUMO1 regulates endothelial function by modulating the overall signals in favor of angiogenesis and homeostatic responses. Am J Transl Res 2013; 5: 427-440.
16. Raij L, Azar S and Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-143.
17. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K and Ritz E. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14: 2833-2842.
18. Yang P, Zhang Y, Pang J, Zhang S, Yu Q, He L, Wagner KU, Zhou Z and Wang CY. Loss of Jak2 impairs endothelial function by attenuating Raf-1/MEK1/Sp-1 signaling along with altered eNOS activities. Am J Pathol 2013; 183: 617-625.
19. Rao X, Zhong J, Zhang S, Zhang Y, Yu Q, Yang P, Wang MH, Fulton DJ, Shi H, Dong Z, Wang D and Wang CY. Loss of methyl-CpG-binding domain protein 2 enhances endothelial angiogenesis and protects mice against hind-limb ischemic injury. Circulation 2011; 123: 2964-2974.
20. Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko T, Atkinson M, Pozzilli P, Zeidler A, Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, Bach JF, Rotter JI, She JX and Wang CY. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 2004; 36: 837-841.
21. Goebel M, Clemenz M and Unger T. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan. Expert Rev Cardiovasc Ther 2006; 4: 615-629.
22. Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK and Weber PC. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol 1999; 6: 233-242.
23. Han KH, Lim JM, Kim WY, Kim H, Madsen KM and Kim J. Expression of endothelial nitric oxide synthase in developing rat kidney. Am J Physiol Renal Physiol 2005; 288: F694-F702.
24. Ito S and Ren Y. Evidence for the role of nitric oxide in macula densa control of glomerular hemodynamics. J Clin Invest 1993; 92: 1093-1098.
25. Terada Y, Tomita K, Nonoguchi H and Marumo F. Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments. J Clin Invest 1992; 90: 659-665.
26. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, Ogawa T, Vallance P and Wilcox CS. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52: 1593-1601.
27. Calnek DS, Mazzella L, Roser S, Roman J and Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-57.
28. Kwon G, Xu G, Marshall CA and McDaniel ML. Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12, 14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. J Biol Chem 1999; 274: 18702-18708.